My hgh cycle

[rocafella]

hey guys, just wanted to post this thread to help some guys out with hgh and what it does, i started HGH today, a pharama brand called norditropin nordilet 5mg/1.5 ml, i'm 24 years old weight 186 pounds, i'm 6.0 tall.

i woke up in the morning after 4 hours of sleep and took 1.5 ius, didn't feel any pain or headache or anything, after and hour i had my carbs, i'm gonna shoot one in the afternoon after my training with 1.5 ius, so that will be 3 ius ed.

the pen was so nice and easy to handle, and the needle, i didn't feel a thing going in, after i injected i felt a little heat in the injected area, and i felt something moving in my stomach.

for now i'm planning to run HGH minimum 6 month, maybe introduce some TEST E with low dosage of 250 or 300 mgs/week after 3 month of taken HGH, or having some anavar .

i will keep you posted with the dosage and the results.

[rocafella]

i'm now doing 4 ius, 2 ius before bed and 2 ius first thing when i wake up

there's no side effect

only hand numb when i first wake up for 2 min

till now the biggest change i saw is in the gym

im carrying mad weights and i feel great. will keep u posted

[ezlimitz]

well I am no expert but I can tell you that more than a few people here might say that you're young enough that you might save your hgh money till your 40th birthday...

[italianstallion32]

Hi,
I'm 22 years old. I am being trained by George Farah and Danny Padilla. I am thinking about taking hgh to bulk up. If money is not a concern and if my plates are closed, are there any dangerous side effects?

[Klimax]

To bulk up gh is not the "answer". But the muscles gained won't be lost and there aren't side effects, if the dosis is low. At 22 buying gh is a waste of money. I'll hope also you're patient, because you can see results after months (or years, if you don't diet and train properly).

[pharm-muscle]

No sides? Here is the list from the package insert of Nutropin
antibody formation

arthralgia

back pain

bleeding

carpal tunnel syndrome

chest pain (unspecified)

depression

diabetes mellitus

diabetic ketoacidosis

dizziness

erythema

fluid retention

glycosuria

gynecomastia

headache

hematuria

hyperglycemia

hypoesthesia

hypoglycemia

hypothyroidism

increased intracranial pressure

infection

injection site reaction

insomnia

musculoskeletal pain

myalgia

nausea/vomiting

pancreatitis

papilledema

paresthesias

peripheral edema

pruritus

rash (unspecified)

rhinitis

secondary malignancy

seizures

skin hyperpigmentation

weakness

[Klimax]

Oh I forgot. Monitorate your glucose and insuline levels in order to make sure you're not developing diabethes and Igf1 to see if gh is working. If a finger becomes bigger or your face becomes strange, it's better you stop taking gh.

[pharm-muscle]

rare but possible...otherwise the FDA wouldnt make them put these in the PI.

For example:
rates of edema or peripheral edema have varied according to the brand of somatropin used and range from 10.8—42%.

[Klimax]

Informing about sides is good, but you should also say if they're frequent. Also headache pills have many possible sides. If you give so many sides (hypo and hyperglicemia?), young people will think: "It won't happen to me.", but if you focuse on the really frequent sides, they'll more scared.

[pharm-muscle]

Agreed! For posterity and educational reasons here is the complete breakdown

Leukemia has been reported in a small number of growth hormone deficient patients treated with somatropin. It is uncertain if this increased risk is related to the pathology of growth hormone deficiency itself, growth hormone therapy, or other associated treatments such as radiation therapy for intracranial tumors. On the basis of current evidence, experts cannot conclude that growth hormone therapy is responsible for this potential secondary malignancy. Patients should also be monitored for malignant transformation of skin lesions (i.e., increased growth of pre-existing nevi). The risk to growth hormone deficient, chronic renal insufficient, or Turner's syndrome patients, if any, remains to be established.

Both fluid retention and peripheral edema have been reported in patients receiving somatropin. Peripheral edema is more common in adults than children. In trials of growth hormone deficient (GHD) adults, rates of edema or peripheral edema have varied according to the brand of somatropin used and range from 10.8—42%. In children with GHD, the rates range from 6.3—8.6%. The edema appears to occur early in therapy and may be transient and/or respond to a dose reduction.

Increased intracranial pressure (intracranial hypertension) with papilledema, visual changes, headache, and nausea/vomiting have been reported in a small number of patients treated with growth hormone products. Symptoms usually occur within the first 8 weeks of initiation of treatment. In all reported cases, symptoms resolved after termination of therapy or a reduction in dose. Funduscopic examination of patients is recommended at the initiation of therapy and periodically throughout treatment.

Arthralgia (13—23%), myalgia (5—15%) , musculoskeletal pain (5—11%), pain and stiffness of the extremities (7.9—14.7%), back pain (3—10%), weakness, and headache (7.7—18.3%) have been commonly associated with somatropin therapy. Some events appear to occur more frequently in adults than in children, particularly arthralgia. In adults treated with somatropin, muscle and joint pain usually occurred early in therapy and tended to be transient or respond to dosage reduction. Pain, swelling and/or stiffness may resolve with analgesic use or a reduction in frequency of dosing with somatropin. In addition, carpal tunnel syndrome (nerve entrapment syndrome), paresthesias (6.7—13%), and hypoesthesia (6—11%) have also been reported.

Metabolic complications may be seen occasionally during somatropin therapy. Hyperglycemia, hypoglycemia, hypothyroidism, glycosuria have been reported. During a 6 month placebo-controlled trial in growth hormone deficient (GHD) adults using the Saizen® brand of somatotropin, approximately 10% of somatropin-treated patients required small upward adjustments of thyroid hormone replacement therapy for preexisting hypothyroidism, and 1 patient was newly diagnosed with hypothyroidism. Additionally, during the trial, 2 patients required upward adjustments of hydrocortisone maintenance therapy (unrelated to intercurrent stress, surgery, or disease) for preexisting hypoadrenalism, and 1 patient was newly diagnosed with adrenal insufficiency. During post-marketing surveillance of various somatropin products, cases of new onset glucose intolerance (hyperglycemia), diabetes mellitus, and exacerbation of pre-existing diabetes mellitus have been reported. Some patients developed diabetic ketoacidosis and diabetic coma. In some patients, these conditions improved when somatropin was discontinued while in others the glucose intolerance persisted; some patients need initiation or adjustment of antidiabetic treatment. In patients with idiopathic short stature, long term treatment with Nutropin® resulted in increases in fasting and postprandial insulin concentrations, but fasting and postprandial glucose concentrations were unchanged. In addition, mean glycosylated hemoglobin concentrations rose slightly during adolescence, as expected. In patients with Turner syndrome treated with Norditropin®, impaired fasting glucose after 4 years of treatment was higher in patients in the highest dose group (22% incidence in the 0.045 mg/kg/day for 1 year followed by 0.067 mg/kg/day thereafter dose group as compared 5% in the 0.045 mg/kg/day dose group).

Seizures have been reported infrequently with Saizen® therapy. In addition, patients taking various brands of somatropin therapy have reported insomnia (roughly 5% in somatropin vs. 0% in placebo), depression (roughly 5% in somatropin vs. 0% in placebo) and dizziness (6.7% in somatropin vs. 5.5% in placebo).

Flu like symptoms have been reported in up to 6—15% of patients; upper respiratory tract infection and rhinitis have been reported at a similar frequency. In patients with Turner Syndrome treated with Humatrope®, there was a statistically increased incidence of otitis media, ear disorders, and surgical procedures as compared to placebo. In addition, in patients with Turner Syndrome treated with Norditropin®, otitis media was also frequently reported. In this study, patients in group 1 (0.045 mg/kg/day for year 1, 0.067 mg/kg/day for year 2, and 0.089 mg/kg/day thereafter) experienced a higher rate of otitis media of 86.4% compared to 78.3% of patients in group 2 (0.045 mg/kg/day for 1 year followed by 0.067 mg/kg/day thereafter) and 69.6% of patients in group 3 (0.045 mg/kg/day). These findings suggest that the risk of otitis media may be increased with higher doses. It should be noted that the otitis media was considered to be serious in 40—50% of reports.

Injection site reaction (pain or burning associated with injection), lipoatrophy, or nodules are associated with the administration of somatropin formulations. Injection site reactions occur in nearly all patients treated with Nutropin Depot™. On average 2—3 injection site adverse reactions were reported per injection. These reactions included nodules (61% of injections), erythema (53%), pain after injection (47%), pain during the injection (43%), bruising (20%), pruritus (13%), lipoatrophy (13%), and swelling or puffiness (8%). The intensity of these reactions was generally rated mild to moderate, with pain during injection occasionally rated as severe (7%).

Antibody formation may occur in approximately 2% of patients receiving somatropin. In patients receiving somatropin for >= 6 months, 4.7% had serum binding of radiolabeled growth hormone, which was more than twice that of controls. In comparison, almost 75% of patients treated with somatrem for >= 6 months had serum binding of radiolabeled growth hormone. Growth hormone antibody binding capacities below 2 mg/L have not been associated with growth attenuation, however, in some cases when binding capacity exceeds 2 mg/L, growth attenuation has been observed. Testing for growth hormone antibodies should be performed in any patient who fails to respond to somatropin therapy.

Skin hyperpigmentation and eczema have been reported in patients taking somatropin therapy. In addition, allergic reactions are possible and include rash (unspecified). In addition, exacerbation of pre-existing psoriasis has been reported in patients taking the Saizen® brand of somatropin.

Bleeding, fibrosis, gynecomastia , hematuria, and acute pancreatitis have been reported rarely. There have been reports of chest pain (unspecified) in roughly 5% of patients treated with selected somatropin products, with no reports of such events the placebo group.

The effects of somatropin (Humatrope®) on bone mineral density (BMD) and bone mineral content (BMC) has been evaluated in patients with adult-onset growth hormone deficiency and adults with childhood-onset GH deficiency still requiring somatropin therapy as adults (transition patients). Men, but not women, in the adult-onset study had an increase of 4% in lumbar spine BMD relative to placebo. No significant change in hip BMD was seen in women or men. In transition patients, patients randomized to 12.5 mcg/kg/day of somatropin, versus 25 mcg/kg/day or placebo, experienced an increase of 2.9% in total BMC; patients in the other two groups did not experience any changes. Increases in lumbar spine BMD and BMC were also statistically significant in the 12.5 mcg/kg/day treatment group. The occurrence of osteoporotic fracture was not studied.

The effect of somatropin (Nutropin® AQ) on visceral adipose tissue has been evaluated in an open-label trial of adult patients with both childhood-onset and adult-onset GH deficiency. Doses of somatropin of up to 0.012 mg/kg per day in women (all of whom received estrogen replacement therapy) and men under age 35 years, and up to 0.006 mg/kg per day in men over age 35 years were administered for 32 weeks. Compared with untreated patients, after 32 weeks visceral adipose tissue (VAT) in patients treated with somatropin decreased by 14.2% (P=0.012). The effect of reducing VAT in adult GHD patients with somatropin on long-term cardiovascular morbidity and mortality has not been determined.

[bighital]

back pain,carpal tunnel syndrome

chest pain (unspecified),dizziness,headache---That what side's I think I been getting from the HGH..

[Klimax]

Wow pharm-muscle. That was very accurate.

[italianstallion32]

back pain,carpal tunnel syndrome

chest pain (unspecified),dizziness,headache---That what side's I think I been getting from the HGH..

Are you close to my age?(22) How long and how much have you been taking with what kind of results?

Does the chest pain, dizziness, headache go away when you are done running the hgh?

Thanks